NZ206923A - "lipopeptide" derivatives and pharmaceutical compositions - Google Patents

"lipopeptide" derivatives and pharmaceutical compositions

Info

Publication number
NZ206923A
NZ206923A NZ206923A NZ20692384A NZ206923A NZ 206923 A NZ206923 A NZ 206923A NZ 206923 A NZ206923 A NZ 206923A NZ 20692384 A NZ20692384 A NZ 20692384A NZ 206923 A NZ206923 A NZ 206923A
Authority
NZ
New Zealand
Prior art keywords
ala
glu
acid
group
cys
Prior art date
Application number
NZ206923A
Other languages
English (en)
Inventor
G Baschang
A Hartmann
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NZ206923A publication Critical patent/NZ206923A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ206923A 1983-01-25 1984-01-24 "lipopeptide" derivatives and pharmaceutical compositions NZ206923A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH39883 1983-01-25

Publications (1)

Publication Number Publication Date
NZ206923A true NZ206923A (en) 1988-05-30

Family

ID=4186110

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ206923A NZ206923A (en) 1983-01-25 1984-01-24 "lipopeptide" derivatives and pharmaceutical compositions

Country Status (18)

Country Link
US (1) US4666886A (Direct)
EP (1) EP0114787B1 (Direct)
JP (1) JPH068316B2 (Direct)
AT (1) ATE67769T1 (Direct)
AU (1) AU569865B2 (Direct)
CA (1) CA1247089A (Direct)
DD (1) DD213917A5 (Direct)
DE (1) DE3485094D1 (Direct)
DK (1) DK31684A (Direct)
ES (3) ES8606398A1 (Direct)
FI (1) FI83524C (Direct)
GR (1) GR81710B (Direct)
HU (1) HU192864B (Direct)
IE (1) IE57092B1 (Direct)
IL (1) IL70766A (Direct)
NZ (1) NZ206923A (Direct)
PT (1) PT78002B (Direct)
ZA (1) ZA84521B (Direct)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602483B2 (en) * 1985-01-18 1990-10-18 Immunetech Pharmaceuticals Immunoregulatory peptides
DE3546150A1 (de) 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
US6074650A (en) * 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3522638A1 (de) * 1985-06-25 1987-01-08 Diamalt Ag Neue somatostatin-derivate
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
CA1315465C (en) * 1987-07-31 1993-03-30 Hans-Helmut Goertz Polymers of oxyalkylated unsaturated quaternary ammonium salts, their preparation and their use
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE4119856A1 (de) * 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
DE59207848D1 (de) * 1991-12-19 1997-02-20 Ciba Geigy Ag Aminosulfonsäurederivate und Verfahren zu ihrer Herstellung
AU666789B2 (en) * 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
EP0604945A1 (en) * 1992-12-28 1994-07-06 Takeda Chemical Industries, Ltd. TAN-1511, its derivatives, production and use thereof
EP0641776A3 (en) * 1993-09-08 1997-05-02 Takeda Chemical Industries Ltd Thioglycerol derivatives.
AU6103896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Manufacture and purification of peptides
US6007819A (en) * 1995-10-17 1999-12-28 Dovetail Technologies, Inc. Methods of inducing immunity using low molecular weight immune stimulants
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
PT921125E (pt) * 1997-12-05 2002-06-28 Hoffmann La Roche Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
FR2816060A1 (fr) * 2000-10-27 2002-05-03 Pf Medicament Procede d'identification de nouvelles molecules se liant au recepteur lox et utilisation de ces molecules
ATE439372T1 (de) * 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
EP1909813A4 (en) * 2005-07-25 2009-09-09 Therimunex Llc PEPTIDYL DIACYLGLYCERIDES
CA2644552C (en) 2006-03-01 2013-05-28 Kyoto University Peptide lipid-containing carrier and method for introducing compound into cells using same
US20080051603A1 (en) * 2006-06-15 2008-02-28 Cell Therapeutics, Inc. Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
KR101080271B1 (ko) * 2009-03-31 2011-11-08 주식회사 웰스킨 다이펩타이드를 유효성분으로 포함하는 자외선에 의한 홍반반응 억제용 화장품 조성물
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
DE102009034779A1 (de) * 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
AU2011232421B2 (en) * 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
EP4144368B1 (en) 2011-01-26 2025-02-26 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
BR112014004782A2 (pt) 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
NL2007536C2 (en) * 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
WO2013131984A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of rabies virus immunogens
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
WO2018183827A1 (en) * 2017-03-31 2018-10-04 Temple University-Of The Commonwealth System Of Higher Education Flexible variable differential transformer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000330B1 (de) * 1977-06-20 1981-08-05 Ciba-Geigy Ag Lipopeptide, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Präparate
HU186585B (en) * 1978-05-18 1985-08-28 Ciba Geigy Ag Process for producing new muramil-peptide derivatives
EP0014815A3 (de) * 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
FR2460290A1 (fr) * 1979-06-29 1981-01-23 Rhone Poulenc Ind Nouveaux tetra- ou pentapeptides, leur preparation et les medicaments qui les contiennent
FR2460288A1 (fr) * 1979-06-29 1981-01-23 Rhone Poulenc Ind Nouveaux dipeptides, leur preparation et les medicaments qui les contiennent

Also Published As

Publication number Publication date
IL70766A0 (en) 1984-04-30
ES8606393A1 (es) 1986-04-01
ES8606398A1 (es) 1986-04-01
ES544194A0 (es) 1986-04-01
FI840259A0 (fi) 1984-01-23
DK31684D0 (da) 1984-01-24
JPH068316B2 (ja) 1994-02-02
AU569865B2 (en) 1988-02-25
DD213917A5 (de) 1984-09-26
FI83524B (fi) 1991-04-15
ES529091A0 (es) 1986-04-01
ATE67769T1 (de) 1991-10-15
IE840157L (en) 1984-07-25
DK31684A (da) 1984-07-26
FI83524C (fi) 1991-07-25
GR81710B (Direct) 1984-12-12
AU2374584A (en) 1984-07-26
ZA84521B (en) 1984-09-26
PT78002B (en) 1986-06-18
EP0114787A3 (en) 1987-05-06
EP0114787A2 (de) 1984-08-01
HU192864B (en) 1987-07-28
US4666886A (en) 1987-05-19
PT78002A (en) 1984-02-01
IE57092B1 (en) 1992-04-22
DE3485094D1 (de) 1991-10-31
FI840259A7 (fi) 1984-07-26
ES544193A0 (es) 1988-09-16
EP0114787B1 (de) 1991-09-25
CA1247089A (en) 1988-12-20
ES8802620A1 (es) 1988-09-16
JPS59139348A (ja) 1984-08-10
IL70766A (en) 1987-08-31

Similar Documents

Publication Publication Date Title
CA1247089A (en) Peptide derivatives
US4439425A (en) Peptide derivatives
JP2744910B2 (ja) ペプチド誘導体類
KR870000372B1 (ko) 아실트리펩타이드의 제조방법
FI94350C (fi) Menetelmä T-soluavustaja-aktiivisuutta omaavien peptidien valmistamiseksi
US4742048A (en) Tetrapeptides and pentapeptides, their preparation and compositions containing them
CA1190221A (en) Phosphoryl compounds, pharmaceutical preparations containing such compounds, and their use
CA1139305A (en) Peptide derivatives
US4461724A (en) Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them
CA2301687A1 (en) Phenethylamine derivatives
EP0253190B1 (en) Partially retro-inverted tuftsin analogues, method for the preparation thereof and pharmaceutical compositions containing them
US4406889A (en) Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
US3488726A (en) R-l-methionyl-glycyl octapeptides related to caerulein and intermediates therefor
AU721261B2 (en) Peptide inhibitors of hematopoietic cell proliferation
EP0004394B1 (en) Psychopharmacological peptides, process for their preparation and their pharmaceutical formulations
CZ553289A3 (en) Peptide exhibiting immunomodulating activity, process of its preparation and pharmaceutical preparation in which it is comprised
JPH0321040B2 (Direct)
EP0531537B1 (en) Hirudin analogue or salt thereof, production thereof, and anticoagulant containing the same as active ingredient
US6342481B1 (en) Oligopeptides derived from C-reactive protein fragments
US3795667A (en) Novel peptide intermediates in the preparation of secretin
NZ220561A (en) Cholecystokinin derivatives
EP0015036A1 (en) Psycho-pharmacological peptides, process for their preparation and therapeutical compositions containing them
JPS6045600A (ja) グルコサミニルムラミルテトラペプチド誘導体